Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Inclusion Criteria

• •Female or male individuals aged ≥18 years at the time of signing the informed consent form
• •Documented evidence of hormone receptor-positive HER2-negative (HR+/HER2-) MBC confirmed
• •Refractory to or relapsed after at least 2, and no more than 4, prior systemic chemotherapy regimens for MBC
• •Should have been previously treated with at least 1 taxane in any setting, at least 1 prior anticancer hormonal treatment in any setting
• •Eligible for one of the chemotherapy options listed in the TPC arm
• •Documented radiographic disease progression after the most recent therapy
• •Measurable disease by CT or MRI in accordance with RECIST v 1.1, bone-only disease is not measurable and is not permitted.
• •Adequate bone marrow function, hepatic and renal function
• •Females must not be lactating or pregnant at Screening or Baseline (as documented by a negative beta human chorionic gonadotropin \[ß-hCG\]